Iqirvo for Primary biliary cholangitis
Quick answer: Iqirvo is used for Primary biliary cholangitis as part of a ppar agonist (pan-ppar) treatment regimen. Elafibranor, a peroxisome proliferator-activated receptor (PPAR) alpha and delta agonist that modulates bile acid synthesis and inflammation The specific dosing for Primary biliary cholangitis is determined by your prescriber based on individual factors.
Why is Iqirvo used for Primary biliary cholangitis?
Iqirvo belongs to the PPAR agonist (pan-PPAR) class. Elafibranor, a peroxisome proliferator-activated receptor (PPAR) alpha and delta agonist that modulates bile acid synthesis and inflammation This action makes it useful for treating or managing Primary biliary cholangitis in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Iqirvo is the right choice for a specific patient depends on the type and severity of Primary biliary cholangitis, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for Primary biliary cholangitis
Common adult dosing range: 80 mg once daily. The actual dose for Primary biliary cholangitis depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Iqirvo medicine page.
What to expect
Iqirvo treatment for Primary biliary cholangitis typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on Primary biliary cholangitis
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Iqirvo is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all PPAR agonist (pan-PPAR) for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Iqirvo
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Iqirvo full prescribing information · All PPAR agonist (pan-PPAR) alternatives
Frequently asked questions
How effective is Iqirvo for Primary biliary cholangitis?
Effectiveness varies by individual response, dose, and severity. Iqirvo is one of several treatment options for Primary biliary cholangitis, supported by clinical evidence within the ppar agonist (pan-ppar) class. Discuss expected response with your prescriber.
How long do I need to take Iqirvo for Primary biliary cholangitis?
Treatment duration depends on the nature of Primary biliary cholangitis — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Iqirvo when used for Primary biliary cholangitis?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Iqirvo for Primary biliary cholangitis?
Yes. Multiple medicines and non-drug options exist for Primary biliary cholangitis. Alternatives within the ppar agonist (pan-ppar) class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.